GLP-1 Regimens for Obesity

(OFF-RAMP Trial)

This trial explores various methods to maintain weight loss for individuals using GLP-1 medications, which aid in weight reduction. Researchers aim to determine whether continuing the full dose, reducing the dose, or switching to another medication (such as phentermine and topiramate) is most effective. The trial suits those who have used GLP-1 medications for at least six months, have obesity (BMI of 30 or more), and have nearly reached their weight goal. Participants will attend three in-person visits and have monthly phone check-ins over a year. The study also includes exercises to help maintain muscle mass. As a Phase 4 trial, this research involves an FDA-approved treatment and seeks to understand how it can benefit more patients.

If you are currently on a GLP-1 medication, you may need to reduce the dose or switch to a different weight loss drug, depending on the group you are assigned to. The trial does not specify stopping other medications, but you cannot participate if you use certain drugs like lithium or metformin.

Previous studies have shown that medications like semaglutide and tirzepatide, which help control blood sugar, are generally safe for most people. However, about half of the users reported at least one side effect. Common side effects include nausea, diarrhea, and vomiting. These side effects varied, with nausea affecting 12% to 24% of users, diarrhea 12% to 22%, and vomiting 2% to 13%.

Another option is a combination of phentermine and topiramate, which has proven effective and generally safe for weight loss. The FDA has approved it for treating obesity, and it can lead to significant weight loss. Many people tolerate this combination well, but like any medication, it may also have side effects.

Lastly, the combination of bupropion and naltrexone has been studied for its safety and effectiveness in managing obesity. It is considered safe for long-term use and well-tolerated. Some studies showed that users experienced significant weight loss compared to those taking a placebo.

Researchers are excited about these treatments for obesity because they offer innovative approaches compared to current options. Traditional treatments often rely on maintaining high-potency GLP-1 agonist therapies, which can be effective but are sometimes limited by availability and cost. The trial is exploring a low-dose, alternate-frequency regimen of GLP-1 agonists like semaglutide and tirzepatide, which aims to maintain effectiveness while potentially reducing side effects and making treatment more accessible. Additionally, another promising treatment involves transitioning patients from GLP-1 agonists to a combination of phentermine and topiramate, or bupropion and naltrexone, which could provide alternative pathways for those who are unable to tolerate or access GLP-1 therapies. These approaches could broaden the range of effective treatment options for obesity, potentially improving patient outcomes and accessibility.

This trial will compare different treatment regimens for obesity. Research has shown that certain medications can aid in weight loss. Participants may receive semaglutide or tirzepatide, both effective for weight management. Semaglutide assists with weight management, while tirzepatide often results in greater weight loss, with some studies noting a 15% reduction. Another trial arm involves transitioning to phentermine with topiramate, which research indicates can lead to sustained weight loss of up to 13% in people with obesity. Additionally, the combination of bupropion and naltrexone, offered to some participants, has been found to cause moderate weight loss, with many losing at least 5%. Each treatment is effective, but some may lead to more significant weight loss than others.³⁶⁷⁸⁹